Stocks of major drug makers and biotech companies tumbled in the first full day of trading after Donald Trump announced that ...

An estimated 828 million adults (420 women, 408 men) had diabetes in 2022, an increase of 630 million since 1990. India (212 ...

Transpire Bio expands headquarters in Weston, adding 6,600 square feet. New executives join, including Stuart Loesch and Todd ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Discover more on Bavarian Nordic's vaccine sales decline, diversification strategy, and strong Travel Health segment, ...

Using cerebrospinal fluid from living patients, researchers have identified specific proteins and genetic pathways involved ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...

President-elect Trump’s decision to nominate Robert F. Kennedy Jr. for Health and Human Services (HHS) secretary will put ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments.

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...